GSK3β genetic variability in patients with Multiple Sclerosis

Neuroscience Letters

Volumn 497, Issue 1, 2011, Pages 46-48

  Galimberti, Daniela ^a   MacMurray, James ^b   Scalabrini, Diego ^a   Fenoglio, Chiara ^a   De Riz, Milena ^a   Comi, Cristoforo ^c   Comings, David ^b   Cortini, Francesca ^a   Villa, Chiara ^a   Serpente, Maria ^a   Cantoni, Claudia ^a   Ridolfi, Elisa ^a   Fardipoor, Ma Hin ^a   Leone, Maurizio ^c   Monaco, Francesco ^c   Bresolin, Nereo ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Carlsbad Science Foundation   (United States)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

GSK3 ; Multiple Sclerosis; Polymorphism; Risk factor

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79956047743     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.04.024     Document Type: Article

References (9)

1. Anderson J.M., Hampton D.W., Patani R., Pryce G., Crowther R.A., Reynolds R., Franklin R.J., Giovannoni G., Compston D.A., Baker D., Spillantini M.G., Chandran S. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008, 131:1736-1748.
2. Anderson J.M., Patani R., Reynolds R., Nicholas R., Compston A., Spillantini M.G., Chandran S. Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol. 2009, 117:583-589.
3. Anderson J.M., Patani R., Reynolds R., Nicholas R., Compston A., Spillantini M.G., Chandran S. Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathol. 2010, 119:591-600.
4. Kwok J.B., Hallupp M., Loy C.T., Chan D.K., Woo J., Mellick G.D., Buchanan D.D., Silburn P.A., Halliday G.M., Schofield P.R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol. 2005, 58:829-839.
5. Lublin F.D., Reingold S.C. For the National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis; results of an international survey. Neurology 1996, 46:907-911.
6. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 2005, 6:777-784.
7. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for MS. Ann. Neurol. 2001, 50:121-127.
8. Schaffer B.A., Bertram L., Miller B.L., Mullin K., Weintraub S., Johnson N., Bigio E.H., Mesulam M., Wiedau-Pazos M., Jackson G.R., Cummings J.L., Cantor R.M., Levey A.I., Tanzi R.E., Geschwind D.H. Association of GSK3B with Alzheimer's disease and Frontotemporal dementia. Arch. Neurol. 2008, 65:1368-1374.
9. Scarpini E., Galimberti D., Baron P., Clerici R., Ronzoni M., Conti G., Scarlato G. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J. Neurol. Sci. 2002, 195:41-46.